Silencing of miR-150-5p Ameliorates Diabetic Nephropathy by Targeting SIRT1/p53/AMPK Pathway

Area of Science:

• Nephrology
• Molecular Biology
• Endocrinology

Background:

• Diabetic nephropathy (DN) is a severe complication of diabetes, leading to end-stage renal disease.
• MicroRNAs (miRNAs) are increasingly recognized as key regulators in the pathogenesis of DN.
• Elevated miR-150-5p levels were observed in serum and urine of DN patients.

Purpose of the Study:

• To investigate the role and mechanism of miR-150-5p in diabetic nephropathy.
• To explore the therapeutic potential of targeting miR-150-5p in DN.

Main Methods:

• In vitro studies using podocytes exposed to high glucose.
• In vivo studies using a mouse model of streptozotocin (STZ)-induced diabetic nephropathy.
• Analysis of miR-150-5p targeting of sirtuin 1 (SIRT1) and its downstream effects on p53 acetylation and autophagy.

Main Results:

• Inhibition of miR-150-5p ameliorated high glucose-induced podocyte injury and STZ-induced DN in mice.
• miR-150-5p was found to directly target the 3' UTR of SIRT1, reducing SIRT1 expression.
• Silencing miR-150-5p enhanced SIRT1-p53 interaction, suppressed p53 acetylation, and stimulated AMPK-dependent autophagy.

Conclusions:

• miR-150-5p plays a detrimental role in DN progression.
• Silencing miR-150-5p exerts a reno-protective effect in DN by targeting SIRT1 and modulating autophagy.
• Targeting miR-150-5p represents a potential therapeutic avenue for diabetic nephropathy.